Myron S. Czuczman

Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

Thomas E. Witzig, Leo I. Gordon, Fernando Cabanillas et al. · Journal of Clinical Oncology · 2002 · 1.2K citations

Medicine, Immunology, Oncology +14

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

Zheng Zhou, Laurie H. Sehn, Alfred Rademaker et al. · Blood · 2013 · 953 citations

Medicine, Hematology, Oncology +14

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

Wyndham H. Wilson, Owen A. O’Connor, Myron S. Czuczman et al. · The Lancet Oncology · 2010 · 853 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment

Thomas A. Davis, Antonio J Grillo-López, Christine A. White et al. · Journal of Clinical Oncology · 2000 · 689 citations

Pharmacy, Hematology, Pharmacotherapy +15

Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma

Thomas E. Witzig, Ian W. Flinn, Leo I. Gordon et al. · Journal of Clinical Oncology · 2002 · 650 citations

Medicine, Hematology, Pharmacotherapy +14